314 related articles for article (PubMed ID: 15371831)
1. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.
Andriole G; Bostwick D; Brawley O; Gomella L; Marberger M; Tindall D; Breed S; Somerville M; Rittmaster R;
J Urol; 2004 Oct; 172(4 Pt 1):1314-7. PubMed ID: 15371831
[TBL] [Abstract][Full Text] [Related]
2. Effect of dutasteride on the risk of prostate cancer.
Andriole GL; Bostwick DG; Brawley OW; Gomella LG; Marberger M; Montorsi F; Pettaway CA; Tammela TL; Teloken C; Tindall DJ; Somerville MC; Wilson TH; Fowler IL; Rittmaster RS;
N Engl J Med; 2010 Apr; 362(13):1192-202. PubMed ID: 20357281
[TBL] [Abstract][Full Text] [Related]
3. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
Musquera M; Fleshner NE; Finelli A; Zlotta AR
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1073-9. PubMed ID: 18588452
[TBL] [Abstract][Full Text] [Related]
4. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
Andriole GL; Roehrborn C; Schulman C; Slawin KM; Somerville M; Rittmaster RS
Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
[TBL] [Abstract][Full Text] [Related]
5. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.
Page ST; Hirano L; Gilchriest J; Dighe M; Amory JK; Marck BT; Matsumoto AM
J Urol; 2011 Jul; 186(1):191-7. PubMed ID: 21575967
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia.
Roehrborn CG; Marks LS; Fenter T; Freedman S; Tuttle J; Gittleman M; Morrill B; Wolford ET
Urology; 2004 Apr; 63(4):709-15. PubMed ID: 15072886
[TBL] [Abstract][Full Text] [Related]
7. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS
Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.
Roehrborn CG; Boyle P; Nickel JC; Hoefner K; Andriole G;
Urology; 2002 Sep; 60(3):434-41. PubMed ID: 12350480
[TBL] [Abstract][Full Text] [Related]
9. Chemoprevention using dutasteride: the REDUCE trial.
Gomella LG
Curr Opin Urol; 2005 Jan; 15(1):29-32. PubMed ID: 15586026
[TBL] [Abstract][Full Text] [Related]
10. Cost utility of prostate cancer chemoprevention with dutasteride in men with an elevated prostate specific antigen.
Svatek RS; Lotan Y
Cancer Prev Res (Phila); 2011 Feb; 4(2):277-83. PubMed ID: 21163937
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
Marberger M; Freedland SJ; Andriole GL; Emberton M; Pettaway C; Montorsi F; Teloken C; Rittmaster RS; Somerville MC; Castro R
BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645
[TBL] [Abstract][Full Text] [Related]
12. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.
Tindall DJ; Rittmaster RS
J Urol; 2008 Apr; 179(4):1235-42. PubMed ID: 18280514
[TBL] [Abstract][Full Text] [Related]
13. Decision analysis of dutasteride use for patients with negative prostate biopsy.
Vickers AJ; Sjoberg DD
Urology; 2015 Feb; 85(2):337-41. PubMed ID: 25623680
[TBL] [Abstract][Full Text] [Related]
14. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
Andriole GL; Marberger M; Roehrborn CG
J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723
[TBL] [Abstract][Full Text] [Related]
15. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.
Andriole GL; Bostwick D; Brawley OW; Gomella L; Marberger M; Montorsi F; Pettaway C; Tammela TL; Teloken C; Tindall D; Freedland SJ; Somerville MC; Wilson TH; Fowler I; Castro R; Rittmaster RS;
J Urol; 2011 Jan; 185(1):126-31. PubMed ID: 21074214
[TBL] [Abstract][Full Text] [Related]
16. [Dutasteride provides chemoprevention].
Werner F
Aktuelle Urol; 2006 Sep; 37(5 Suppl):18. PubMed ID: 23646395
[No Abstract] [Full Text] [Related]
17. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.
Roehrborn CG; Andriole GL; Wilson TH; Castro R; Rittmaster RS
Eur Urol; 2011 Feb; 59(2):244-9. PubMed ID: 21093145
[TBL] [Abstract][Full Text] [Related]
18. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.
Muller RL; Gerber L; Moreira DM; Andriole G; Castro-Santamaria R; Freedland SJ
Eur Urol; 2012 Nov; 62(5):757-64. PubMed ID: 22658758
[TBL] [Abstract][Full Text] [Related]
19. Dutasteride: a novel dual inhibitor of 5alpha-reductase for benign prostatic hyperplasia.
Djavan B; Milani S; Fong YK
Expert Opin Pharmacother; 2005 Feb; 6(2):311-7. PubMed ID: 15757426
[TBL] [Abstract][Full Text] [Related]
20. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial.
Fleshner N; Gomella LG; Cookson MS; Finelli A; Evans A; Taneja SS; Lucia MS; Wolford E; Somerville MC; Rittmaster R;
Contemp Clin Trials; 2007 Nov; 28(6):763-9. PubMed ID: 17573244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
